Ragon Institute

The Ragon Institute was founded in February 2009 through a $100 million gift – the largest gift in Massachusetts General Hospital (MGH) history{{cite news|url=http://archive.boston.com/news/local/massachusetts/articles/2009/02/04/100m_gift_bolsters_aids_fight/|title=$100m gift bolsters AIDS fight|first=Stephen|last=Smith|newspaper=Boston.com |date=4 February 2009|publisher=|accessdate=20 May 2019|via=The Boston Globe}} – from the Phillip T. and Susan M. Ragon Institute Foundation. Administratively based at MGH, the Ragon Institute incorporates the work of the Partners AIDS Research Center at MGH.{{cite web |last=Trafton |first=Anne |date=10 February 2015 |title=A new way of tackling HIV |url=https://www.weforum.org/stories/2015/02/a-new-way-of-tackling-hiv/ |access-date=29 April 2025 |website=World Economic Forum }} Instead of the typical academic approach, in which individual scientists work independently, the Ragon Institute includes engineering disciplines to facilitate new experimental approaches and incorporate fresh ways of viewing complex biological systems, with the goal of rapidly advancing innovative, interdisciplinary research to revolutionize the field of immunology.{{Cite web |last=harvardgazette |date=2009-02-05 |title=$100 million gift to launch innovative search for AIDS vaccine |url=https://news.harvard.edu/gazette/story/2009/02/100-million-gift-to-launch-innovative-search-for-aids-vaccine/ |access-date=2025-04-29 |website=Harvard Gazette |language=en-US}}{{cite journal |last=Flier |first=Jeffrey S. |date=Winter 2023 |title=The Diversity of Institutions Conducting Biomedical Research |url=https://muse.jhu.edu/article/884004/pdf |journal=Perspectives in Biology and Medicine |publisher=Johns Hopkins University Press |volume=66 |issue=1 |pages=58–88 |doi=10.1353/pbm.2023.0004 |pmid=38662009 |access-date=29 April 2025}}{{Cite web |date=2009-02-04 |title=Mass. General, MIT and Harvard launch innovative effort to search for AIDS vaccine |url=https://news.mit.edu/2009/ragon-0204 |access-date=2025-04-29 |website=MIT News {{!}} Massachusetts Institute of Technology |language=en}}{{Cite web |date=2009-02-04 |title=Alum's $100 million gift targets AIDS vaccine |url=https://news.mit.edu/2009/alums-100-million-gift-targets-aids-vaccine |access-date=2025-04-29 |website=MIT News {{!}} Massachusetts Institute of Technology |language=en}}

In 2012, the Ragon Institute launched FRESH (Females Rising through Education, Support, and Health) in South Africa to connect HIV vaccine research with efforts to reduce poverty, a major driver of infection. Based in a former black township near Durban, FRESH trains young women in life skills, computer skills, and HIV prevention, while also working to detect early HIV infections and advance biomedical understanding. The program has helped over 1,200 women, most of whom have stayed uninfected and moved on to jobs or school.{{Cite web |last=Bergman |first=Mary Todd |date=2019-09-19 |title=Ragon Institute receives major gift to expand research into autoimmune diseases |url=https://news.harvard.edu/gazette/story/2019/09/ragon-institute-receives-major-gift-to-expand-research-into-autoimmune-diseases/ |access-date=2025-04-29 |website=Harvard Gazette |language=en-US}}

In January 2013, the Ragon Institute completed its relocation to 400 Technology Square in Cambridge, Massachusetts.{{Cite web|date=2013-06-19|title=Space to Collaborate: Ragon Institute Moves to Cambridge - MGH Giving|url=https://giving.massgeneral.org/space-to-collaborate-ragon-institute-moves-to-cambridge/|access-date=2020-07-07|website=Massachusetts General Hospital Giving}}

On March 21, 2013, researchers at the Ragon Institute of MGH, MIT, and Harvard University introduced a new method for identifying potential HIV vaccine targets. The team, led by Arup K. Chakraborty, developed a computational technique to analyze viral protein sequences, helping to identify weak points in viral strains that could be exploited for vaccine development. By understanding how different viral strains reproduce in the body, the researchers aim to design protein fragments (peptides) targeting these vulnerabilities, with plans to test them in animals.{{Cite web |date=2013-03-22 |title=Study offers new way to discover HIV vaccine targets |url=https://news.mit.edu/2013/new-way-to-discover-hiv-vaccine-targets-0321 |access-date=2025-04-29 |website=MIT News {{!}} Massachusetts Institute of Technology |language=en}}

In 2016, Dr. Facundo Batista joined the Ragon Institute as Scientific Director, strengthening its research capabilities and commitment to advancing immunology.{{Cite web |title=Germline-Targeting Approach Defined for HIV Vaccine |url=https://www.vax-before-travel.com/hiv-vaccine-germline-targeting-strategy-aims-stimulate-germline-b-cells-are-capable-maturing-cells |access-date=2025-04-29 |website=www.vax-before-travel.com |language=en-US}}

On May 2, 2019, Massachusetts General Hospital received a $200 million donation by Phillip T. (Terry) and Susan M. Ragon to endow the Ragon Institute of MGH, MIT, and Harvard.{{Cite web |last=Affairs |first=MGH News and Public |date=2019-05-02 |title=Mass General Receives $200 Million for Ragon Institute |url=https://giving.massgeneral.org/stories/ragon-institute-200-million-donation |access-date=2025-04-29 |website=Massachusetts General Hospital Giving |language=en}}

At the same time, researchers at Harvard Medical School, based at the Ragon Institute of MGH, MIT, and Harvard, identified specific amino acids in the HIV protein structure that are crucial for the virus's function and replication. They found that the immune systems of individuals who can naturally control HIV infection target these amino acids with CD8 T cells, even in those who don't carry the HLA-B protein variants typically linked to HIV control. The findings, published in Science.{{Cite web |date=2019-05-02 |title=HIV Control {{!}} Harvard Medical School |url=https://hms.harvard.edu/news/hiv-control |access-date=2025-04-29 |website=hms.harvard.edu |language=en}}{{Cite journal |last1=Gaiha |first1=Gaurav D. |last2=Rossin |first2=Elizabeth J. |last3=Urbach |first3=Jonathan |last4=Landeros |first4=Christian |last5=Collins |first5=David R. |last6=Nwonu |first6=Chioma |last7=Muzhingi |first7=Itai |last8=Anahtar |first8=Melis N. |last9=Waring |first9=Olivia M. |last10=Piechocka-Trocha |first10=Alicja |last11=Waring |first11=Michael |last12=Worrall |first12=Daniel P. |last13=Ghebremichael |first13=Musie S. |last14=Newman |first14=Ruchi M. |last15=Power |first15=Karen A. |date=2019-05-03 |title=Structural topology defines protective CD8+ T cell epitopes in the HIV proteome |journal=Science |volume=364 |issue=6439 |pages=480–484 |doi=10.1126/science.aav5095|pmid=31048489 |pmc=6855781 }}{{Cite web |date=2022-01-24 |title=Deep dive into HIV's hidden DNA finds that some people could eventually drop their drugs |url=https://www.aidsmap.com/news/jan-2022/deep-dive-hivs-hidden-dna-finds-some-people-could-eventually-drop-their-drugs |access-date=2025-04-29 |website=aidsmap.com |language=en}}

On July 17, 2019, Swiss lawyer Ursula Brunner made a $5 million donation to the Ragon Institute of MGH, MIT, and Harvard. The gift will create the Brunner Fund for Medical Discovery, Education, and Social Good, supporting the institute's FRESH Program.{{Cite web |last=McCafferty |first=Nicola |date=2019-07-30 |title=Ragon Institute Gift Provides Support and Flexibility |url=https://giving.massgeneral.org/stories/ragon-institute-gift-supports-fresh |access-date=2025-04-29 |website=Massachusetts General Hospital Giving |language=en}}

On April 22, 2020, researchers from MIT, the Ragon Institute of MGH, MIT, and Harvard, and the Broad Institute of MIT and Harvard identified specific cells that are more susceptible to infection by the SARS-CoV-2 virus, which causes COVID-19. By analyzing RNA data from various cell types, the team pinpointed cells in the lungs, nasal passages, and intestines that express high levels of the two proteins that allow the virus to enter human cells.{{Cite web |date=2020-04-22 |title=Researchers identify cells likely targeted by Covid-19 virus |url=https://news.mit.edu/2020/researchers-cells-targeted-covid-19-0422 |access-date=2025-04-29 |website=MIT News {{!}} Massachusetts Institute of Technology |language=en}}

In April 2021, at the CROI conference, Xu Yu, M.D., from the Ragon Institute (a collaboration between Massachusetts General Hospital, MIT, and Harvard), presented groundbreaking findings about "elite controllers"—individuals with HIV who naturally suppress the virus without the need for medication. Among these controllers, two individuals suppressed the virus so effectively that no active virus could be detected in their systems, even at very low levels.{{Cite web |date=2021-04-06 |title=Are People Living With HIV Ready to Contribute to the Next Step in Cure Trials? |url=https://www.thebody.com/article/people-with-hiv-cure-trials |access-date=2025-04-29 |website=TheBody |language=en}}  

At the same year, the Ragon Institute began construction on a new research facility, designed to provide expanded laboratory space, enhance collaboration, and support a growing community of scientists, engineers, and clinicians.{{Cite web |date=2024-06-21 |title=New Ragon Institute building opens in the heart of Kendall Square |url=https://news.mit.edu/2024/new-ragon-institute-building-opens-in-kendall-square-0621 |access-date=2025-04-29 |website=MIT News {{!}} Massachusetts Institute of Technology |language=en}}

On January 22, 2024, ReiThera Srl, the Ragon Institute, and IAVI announced a collaboration to develop a novel HIV vaccine candidate. The vaccine will use ReiThera's GRAd vector and HIV T-cell epitopes identified by the Ragon Institute, with funding from the Bill & Melinda Gates Foundation. ReiThera will handle vector engineering, process development, and GMP manufacturing, while the Ragon Institute will lead preclinical development. IAVI will sponsor and conduct a Phase 1 clinical trial to assess the vaccine's safety and immunogenicity.{{Cite web |title=ReiThera Srl, the Ragon Institute and IAVI announce collaboration to advance highly networked T-cell HIV vaccine candidate towards Phase 1 clinical evaluation |url=https://www.iavi.org/press-release/reithera-srl-the-ragon-institute-and-iavi-announce-collaboration-to-advance-highly-networked-t-cell-hiv-vaccine-candidate-towards-phase-i-clinical-evaluation/ |access-date=2025-04-29 |website=IAVI |language=en}}

On June 24, 2024, the Ragon Institute celebrated its 15th anniversary and opened a 300,000-square-foot building in Cambridge, on Kendall Square at 600 Main St. and includes a lab and workspace and is Leed Gold certified by the U.S. Green Building Council.{{Cite web |last=Simon |first=Clea |date=2024-06-24 |title=How Ragon Institute's new building aids its mission |url=https://news.harvard.edu/gazette/story/2024/06/how-ragon-institutes-new-building-aids-its-mission-cross-disciplinary-infectious-diseases-immunology/ |access-date=2025-04-29 |website=Harvard Gazette |language=en-US}}{{Cite web |title=Ragon Institute of Mass General Brigham, MIT, and Harvard celebrates opening of new headquarters |url=https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/ragon-institute-celebrates-new-headquarters |access-date=2025-04-29 |website=www.massgeneralbrigham.org}}{{Cite web |url=https://www.bizjournals.com/boston/news/2024/06/18/ragon-instutute-hq-mgb-harvard-mit.html |access-date=2025-04-29 |website=www.bizjournals.com}}

On August 2024, Terry Ragon announced that he is funding HIV cure research through his Ragon Institute and donated around $400 million to the cause. Ragon has referred to this initiative as a “Manhattan Project on HIV,” with clinical trials for a therapeutic vaccine scheduled for 2025.{{Cite web |last=Straube |first=Trent |date=2024-08-13 |title=Billionaire Terry Ragon Funds HIV Cure Research Based on Elite Controllers |url=https://www.poz.com/article/billionaire-terry-ragon-funds-hiv-cure-research-based-elite-hiv-controllers |access-date=2025-04-29 |website=POZ |language=en}}{{Cite web |last=Jennings |first=Katie |title=This Secretive Billionaire Thinks He Can Cure HIV. Here's Why. |url=https://www.forbes.com/sites/katiejennings/2024/08/07/this-secretive-billionaire-thinks-he-can-cure-hiv-heres-why/ |access-date=2025-04-29 |website=Forbes |language=en}}

In November 2024, the Ragon Institute together with Tecnológico de Monterrey signed an agreement to collaborate on doctoral studies, research programs, academic exchanges, and joint research projects to bring advanced immune system research to Latin America.{{Cite web |last=Jaber |first=Inés Gutiérrez |date=2024-11-13 |title=How a Collaboration in Immunology Can Transform Health Care in Latin America |url=https://tecscience.tec.mx/en/health/ragon-institute-tec-de-monterrey/ |access-date=2025-04-29 |website=TecScience |language=en}}{{Cite web |title=Health innovation: Tec and Ragon Institute (MGH, MIT, and Harvard) |url=https://conecta.tec.mx/en/news/national/institution/health-innovation-tec-and-ragon-institute-mgh-mit-and-harvard |access-date=2025-04-29 |website=conecta.tec.mx |language=en}}{{Cite web |last=Garza-Salazar |first=David |date=2025-01-12 |title=Global North-South collaborations boost discovery and deployment |url=https://www.timeshighereducation.com/opinion/global-north-south-collaborations-boost-discovery-and-deployment |access-date=2025-04-29 |website=Times Higher Education (THE) |language=en}}

On January 29, 2025, researchers at the Ragon Institute and MIT's Jameel Clinic developed MUNIS, a deep-learning model that improves T cell epitope prediction. This model has the potential to accelerate vaccine development for infectious diseases. The findings were published in Nature Machine Intelligence.{{Cite web |date=2025-01-29 |title=New Tool Predicts T Cell Epitopes with Unprecedented Accuracy |url=https://www.azorobotics.com/News.aspx?newsID=15672 |access-date=2025-04-29 |website=AZoRobotics |language=en}}{{Cite journal |last1=Wohlwend |first1=Jeremy |last2=Nathan |first2=Anusha |last3=Shalon |first3=Nitan |last4=Crain |first4=Charles R. |last5=Tano-Menka |first5=Rhoda |last6=Goldberg |first6=Benjamin |last7=Richards |first7=Emma |last8=Gaiha |first8=Gaurav D. |last9=Barzilay |first9=Regina |date=February 2025 |title=Deep learning enhances the prediction of HLA class I-presented CD8+ T cell epitopes in foreign pathogens |journal=Nature Machine Intelligence |language=en |volume=7 |issue=2 |pages=232–243 |doi=10.1038/s42256-024-00971-y |issn=2522-5839 |pmc=11847706 |pmid=40008296}}{{Cite web |date=2025-01-29 |title=New AI tool promises faster vaccine development by predicting T cell epitopes |url=https://www.news-medical.net/news/20250129/New-AI-tool-promises-faster-vaccine-development-by-predicting-T-cell-epitopes.aspx |access-date=2025-04-29 |website=News-Medical |language=en}}

Researchers, staff, and collaborators occupy approximately 74,675 sq ft of the facility at 400 Technology Square, Cambridge, Massachusetts, consisting of floors 7–10, half the 1st floor, and 3,000 sq ft on the basement level. The building also features a Biosafety Level 3 (BL3) lab, which will provide scientists in the community access to a dedicated 12-color high-speed cell sorter and microscopy. The first floor has a 160-seat auditorium with audio-visual and conferencing capabilities which is used for weekly seminars as well as community events.{{Cite web |last=Goldsmith |first=Paul |date=2024-07-02 |title=The Ragon Institute Celebrates 15 years with Opening of New Building - Massachusetts General Hospital Giving % |url=https://giving.massgeneral.org/stories/ragon-institute-celebrates-new-building |access-date=2025-04-29 |website=Massachusetts General Hospital Giving |language=en}}{{Cite web |date=2024-06-21 |title=New Ragon Institute building opens in the heart of Kendall Square |url=https://news.mit.edu/2024/new-ragon-institute-building-opens-in-kendall-square-0621 |access-date=2025-04-29 |website=MIT News {{!}} Massachusetts Institute of Technology |language=en}}{{Cite web |title=The Ragon Institute of Mass General, MIT and Harvard |url=https://www.payette.com/project/ragoninstitute/ |access-date=2025-04-29 |website=Payette |language=en}}

The Ragon Institute operates on harnessing the immune system to prevent and cure human disease through interdisciplinary collaboration. Scientists from immunology, genetics, infectious diseases, and computational biology work together to advance global health initiatives.{{Cite web |date=2009-06-18 |title=Newly formed Ragon Institute hosts symposium on computational immunology |url=https://news.mit.edu/2009/ragon-0618 |access-date=2025-04-29 |website=MIT News {{!}} Massachusetts Institute of Technology |language=en}}

The Institute is structured around three core research programs:{{cite web |date=13 November 2024 |title=Tec de Monterrey strengthens health research through a unique collaboration in Latin America with the Ragon Institute |url=https://newsroom.itesm.mx/Estenografas/2024.11.13%20Tec%20de%20Monterrey%20strengthens%20health%20research%20through%20a%20unique%20collaboration%20in%20Latin%20America%20with%20the%20Ragon%20Institute.pdf |access-date=29 April 2025 |publisher=Tecnológico de Monterrey}}

1. Program for Immunophysiology and Disease: This program investigates immune system complexities to prepare for global health threats. It focuses on understanding immune homeostasis, strengthening immune responses against pathogens, and addressing immune dysfunctions.
2. Program for Patient-Focused Immunology: By bridging clinical observations and laboratory research, this program develops patient-centered therapies. It includes testing therapeutic interventions through clinical trials, conducting translational studies to develop novel treatments, and addressing health equity through social and behavioral research.
3. Program for Immune Engineering: This program leverages scientific discoveries to develop innovative diagnostics and therapies, including the creation of immune-based vaccines, the development of disease detection tools, and the exploration of non-vaccine immune therapies.

The Ragon Institute has 24 research labs led by prominent principal investigators. These labs focus on various areas of immunology and infectious diseases, including HIV, cancer, malaria, tuberculosis, COVID-19, autoimmune diseases, and emerging viruses like Zika and Ebola. Researchers at the Institute work on topics such as immune response mechanisms, vaccine development, host-pathogen interactions, immune therapy, and clinical trials, collaborating across disciplines to advance global health initiatives. Each lab brings expertise in molecular biology, immunogenetics, and clinical research.{{Cite web |title=Health innovation: Tec and Ragon Institute (MGH, MIT, and Harvard) |url=https://conecta.tec.mx/en/news/national/institution/health-innovation-tec-and-ragon-institute-mgh-mit-and-harvard |access-date=2025-04-29 |website=conecta.tec.mx |language=en}}

With 12 labs dedicated to various research sectors, the Ragon Institute is a hub for innovation, where PhD fellows lead cutting-edge studies and frequently publish their findings, securing ongoing grants to propel their work forward. The Institute fosters a collaborative environment that brings together experts from engineering, medicine, and various research disciplines, ensuring a comprehensive approach to solving some of the world’s most pressing health issues.

Launched in 2012, the Females Rising through Education, Support, and Health (FRESH) program operates in KwaZulu-Natal, South Africa, where young women face a high risk of contracting HIV.{{Cite journal |last1=Dubé |first1=Karine |last2=Mthimkhulu |first2=Deli |last3=Ngcobo |first3=Wiseman |last4=Mindry |first4=Deborah |last5=Maphalala |first5=Luyanda |last6=Pillay |first6=Vanessa |last7=Tran |first7=Whitney |last8=Korolkova |first8=Ana |last9=Ndung'u |first9=Thumbi |last10=Dong |first10=Krista |date=2023-07-29 |title='With this study, we have hope that something is coming': community members' perceptions of HIV cure-related research in Durban, South Africa - a qualitative focus group study |journal=HIV Research & Clinical Practice |volume=24 |issue=1 |pages=2243046 |doi=10.1080/25787489.2023.2243046 |issn=2578-7470 |pmc=10433450 |pmid=37555592}} FRESH integrates scientific research with life-skills and job training, aiming to understand early immune responses to HIV and empower young women by providing access to HIV prevention medications (PrEP) and development resources.{{Cite web |title=FRESH program combines basic science with social benefits for women at risk of HIV |url=https://www.eurekalert.org/news-releases/682506 |access-date=2025-04-29 |website=EurekAlert! |language=en}}  

In 2022, Ragon International expanded its efforts with the Baby U! program, addressing the challenge of preterm birth (PTB) in South Africa, where the PTB rate is notably high. This program recruits pregnant women in Umlazi Township to study the immune correlates of PTB, aiming to develop early biomarkers for predicting and preventing preterm births. Alongside research, Baby U! offers prenatal care and addresses broader maternal and neonatal health disparities.

The ITEACH program, established in 2005 at Edendale Hospital in KwaZulu-Natal, South Africa, focuses on improving access to HIV and TB treatment and prevention. It partners with local health providers, traditional Zulu healers, and community stakeholders to reduce the impact of these diseases.{{Cite journal |last1=Dong |first1=Krista |last2=Thabethe |first2=Zinhle |last3=Hurtado |first3=Rocio |last4=Sibaya |first4=Thobe |last5=Dlwati |first5=Hlubi |last6=Walker |first6=Bruce |last7=Wilson |first7=Doug |date=2007-12-01 |title=Challenges to the Success of HIV and Tuberculosis Care and Treatment in the Public Health Sector in South Africa |url=https://academic.oup.com/jid/article-abstract/196/Supplement_3/S491/2191871?redirectedFrom=fulltext |journal=The Journal of Infectious Diseases |volume=196 |issue=Supplement_3 |pages=S491–S496 |doi=10.1086/521111 |pmid=18181699 |issn=0022-1899}}{{cite journal |last=Dong |first=Krista |author2=Thabethe, Zinhle |author3=Hurtado, Rocio |author4=Sibaya, Thobe |author5=Dlwati, Hlubi |author6=Walker, Bruce |author7=Wilson, Doug |date=1 December 2007 |title=Challenges to the Success of HIV and Tuberculosis Care and Treatment in the Public Health Sector in South Africa |url=https://www.researchgate.net/publication/5668125 |journal=The Journal of Infectious Diseases |volume=196 |issue=Supplement 3 |pages=S491–S496 |doi=10.1086/521111 |pmid=18181699 |access-date=29 April 2025}} ITEACH trains traditional healers to integrate modern HIV and TB prevention methods, reaching patients who may not seek conventional care. The program also supports healthcare efforts by deploying Treatment Warriors and playing a key role in COVID-19 education.{{Cite web |date=2009-05-21 |title=Using mobile phones in HIV care and prevention |url=https://www.aidsmap.com/news/may-2009/using-mobile-phones-hiv-care-and-prevention |access-date=2025-04-29 |website=aidsmap.com |language=en}}

The Connect Africa Scholarship supports early-career African scientists by offering travel and skills-building opportunities. This program helps researchers enhance their expertise and contribute to global health technologies, while promoting sustainable scientific leadership in under-resourced regions.{{Cite web |title=AHRI {{!}} Connect Africa Scholarships |url=https://www.ahri.org/connect-africa-scholarships/ |access-date=2025-04-29 |website=Africa Health Research Institute |language=en}}

The Ragon Institute advances global health by partnering with institutions worldwide, particularly in regions heavily impacted by HIV, TB, and other infectious diseases.{{Cite web |title=ReiThera Srl, the Ragon Institute and IAVI announce collaboration to advance highly networked T-cell HIV vaccine candidate towards Phase 1 clinical evaluation |url=https://www.iavi.org/press-release/reithera-srl-the-ragon-institute-and-iavi-announce-collaboration-to-advance-highly-networked-t-cell-hiv-vaccine-candidate-towards-phase-i-clinical-evaluation/ |access-date=2025-04-29 |website=IAVI |language=en}} Key collaborations in South Africa include support for the Africa Health Research Institute (AHRI), HIV Pathogenesis Programme (HPP), and the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), where the Ragon Institute plays a pivotal role in research and training.{{Cite web |title=Inter-disciplinary/approaches to understanding the global burden of HIV and youth 2025 |url=https://www.santheafrica.org/our-events/inter-disciplinary-approaches-to-understanding-the-global-burden-of-hiv-and-youth-2025/ |access-date=2025-04-29 |website=SANTHE (Sub-Saharan African Network for TB/HIV Research Excellence)}} These partnerships aim to address health crises and build local scientific capacity, exemplified by initiatives like the Connect Africa Scholarship, fostering the next generation of African scientists. The Ragon Institute’s international collaborations began with Dr. Bruce Walker’s early work in KwaZulu-Natal.{{Cite web |date=2018-01-17 |title=Bruce Walker, M.D. |url=https://www.i4cacure.org/principal-investigat/bruce-walker-m-d/ |access-date=2025-04-29 |website=I4C Immunotherapy for HIV Cure |language=en-US}}

{{Reflist}}

• [https://ragoninstitute.org/ Official website of the Ragon Institute of MGH, MIT, and Harvard]

{{coord|42.364|-71.092|type:landmark_region:US-MA|display=title}}

{{authority control}}

Category:Medical research institutes in Massachusetts

Category:Massachusetts General Hospital

Category:Vaccination-related organizations based in the United States

Category:HIV/AIDS research organisations

Category:Immunology organizations

Category:Harvard University research institutes

Category:Massachusetts Institute of Technology research institutes

Category:Non-profit organizations based in Massachusetts

Category:Organizations based in Boston

Category:Science and technology in Massachusetts

Category:Research institutes established in 2009

Category:Scientific organizations established in 2009

Category:2009 establishments in Massachusetts

Category:HIV/AIDS organizations in the United States